Replimune stock doubled to $9.00 after FDA accepted its resubmitted application for melanoma drug RP1, with decision expected ...

Today Dominic is back with a look at Palit's rtx 2070 Super JS, currently on offer for under £480 here in the UK. If you want ...

Replit expects to hit $1 billion in revenue next year as AI coding products replace old tools.

Shares of Replimune Group are rising Monday after the clinical stage biotechnology company shared an important regulatory ...

Our client is a global leader in digital marketing and client reporting solutions, empowering financial professionals to enhance investor engagement and retention. With operations spanning four ...

Replimune Group’s REPL share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics ...

On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...

If you are following Replimune Group (REPL) right now, you’re not alone. The company’s recent announcement about completing a Type A meeting with the FDA on its lead drug candidate, RP1, has put it ...

Fintel reports that on September 19, 2025, JP Morgan downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Neutral to Underweight. Analyst Price Forecast Suggests 110.57% Upside As of ...

At least 187 code packages made available through the JavaScript repository NPM have been infected with a self-replicating worm that steals credentials from developers and publishes those secrets on ...